
Cencora Inc (COR) Stock Forecast & Price Target
Cencora Inc (COR) Analyst Ratings
Bulls say
Cencora is a strong competitor in the US pharmaceutical wholesale industry, with a dominant market share alongside McKesson and Cardinal Health. The recent acquisition of Alliance Healthcare has also expanded its presence in Europe, demonstrating its commitment to international growth. Though it lacks the high-growth, high margin businesses of its competitors, Cencora's leading specialty distribution, particularly in the retina and oncology MSO space, insulates it from PBM steerage risk. Additionally, its expansion into patient support and data analytics services positions the company for continued growth and adaptability in a changing healthcare landscape. The potential for biosimilar launches and upcoming patent cliffs also presents opportunities for margin expansion. However, potential regulatory changes and scrutiny could negatively impact distribution margins and fee structures, and COR's lack of differentiation from its peers may limit its upside potential. Based on these factors, the analyst initiates coverage with a Sector Perform rating and a price target of $330, reflecting a slight premium to its current PE multiples.
Bears say
Cencora is facing intensified FTC scrutiny and competition from McKessonand Cardinal Health in the US pharmaceutical wholesale industry, with the recent sale ofMWI Animal Health to Covetrus putting further pressure on regulatory hurdles and market share concentration. While the company has expanded internationally and into services such as commercialization and global specialty drug logistics, its lack of diversified growth drivers and potential risks from changes to pharmaceutical pricing and reimbursement policies add to our negative outlook.
This aggregate rating is based on analysts' research of Cencora Inc and is not a guaranteed prediction by Public.com or investment advice.
Cencora Inc (COR) Analyst Forecast & Price Prediction
Start investing in Cencora Inc (COR)
Order type
Buy in
Order amount
Est. shares
0 shares